Lack of anti-multiple myeloma effect of siltuximab in clinical trials could be explained by emergence of IL-6-independent subclones or substitution for IL-6 by other IL-6 family cytokines that utilize gp130 as a shared signal transducer [60]. This evidence concerns the gene IL6 and plasma cell myeloma.